CELC
Celcuity Inc.
A clinical-stage biotech developing gedatolisib, a drug aimed at blocking cancer-driving cell signals to treat advanced breast and prostate cancer. Founded in 2012 by Brian Sullivan and Lance Laing, the company first built CELsignia, a tool that reads living tumor cells, before pivoting to drug development. Its name blends "cell" and "acuity" — a nod to the sharp, precise view the founders wanted of a tumor's inner workings.
CUSIP: 15102K100HealthcareUS1 holder
Total Value
$1.96M
Total Shares
17.2K
Net Share Change
+12.5K
Activity
1 buying
Investor
Value
Shares
Weight
Change
